Clinical Trials Logo
  1. Home
  2. Age-Related Macular Degeneration
  3. NCT05437302
  4. Details
NCT05437302 Clinical Trial

Effectiveness of Prism Spectacles in Patients With Age Related Macular Degeneration

Age-Related Macular Degeneration Clinical Trial

Official title:
Effectiveness of Prism Spectacles in Patients With Age Related Macular Degeneration

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05437302
Other study ID # Ufaisalabad
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 4, 2021
Est. completion date May 31, 2022

Study information
Verified date June 2022
Source University of Faisalabad
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A study is conducted to determine the effectiveness of prism spectacles in improving visual acuity with age related macular degeneration patients and to assess the improvement in quality of life in patients by using prism spectacles.

Description:

A random sampling technique will be used to allocate patient in interventional and non-interventional group. The diagnosed patients of age-related macular degeneration are assessed for prism spectacles for near vision and prism glasses will be dispensed to the patients. Each subject will be interviewed to fill the Proforma after taking the informed consent. The results of this study will show the effectiveness of prism glasses in patients with age related macular degeneration in their daily routine near work as compared to conventional glasses.

Recruitment information / eligibility
Status Completed
Enrollment 80
Est. completion date May 31, 2022
Est. primary completion date May 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: - Patients having age >50 years with age related macular degeneration. - Patients of both genders (male and female). - Participants who will be willing to give informed consent for participation in the study. Exclusion Criteria: - Presence of all ocular disease and systemic ocular pathologies able to impair visual function. - Presence of disorders causing choroidal neovascularization other than age related macular degeneration. - Patients with mental illness, dementia, and severe physical limitations

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• prism spectacle
a prism is dispensed in prescription glasses

Locations
Country Name City State
Pakistan Mehreen Rawalpindi

Sponsors (1)
Lead Sponsor Collaborator
University of Faisalabad

Country where clinical trial is conducted

Pakistan, 

Outcome
Type Measure Description Time frame Safety issue
Primary Visual Acuity Near and Distance visual acuity are measured in log Mar units. Four week
Primary Visual Functional Quality of life (VFQOL) VFQOL is measured by a validated tool VFQOL-25. Four weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05984927 - NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration Phase 1/Phase 2
Active, not recruiting NCT05536297 - Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy Phase 3
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Completed NCT04005352 - Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) Phase 3
Withdrawn NCT02873351 - A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration Phase 2
Active, not recruiting NCT02802657 - Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration Phase 4
Not yet recruiting NCT02864472 - Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose Phase 4
Recruiting NCT01521065 - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Phase 2
Completed NCT02035722 - Intravitreal Injections-related Anxiety Phase 2/Phase 3
Completed NCT01445548 - Sirolimus for Advanced Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT01175395 - 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) Phase 1/Phase 2
Recruiting NCT01048476 - Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration Phase 1/Phase 2
Active, not recruiting NCT01174407 - Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration N/A
Terminated NCT00712491 - Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT00345176 - Age-Related Eye Disease Study 2 (AREDS2) Phase 3
Completed NCT02140151 - Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration Phase 1/Phase 2
Completed NCT02555306 - A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration Phase 1/Phase 2
Recruiting NCT04796545 - Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration N/A
Completed NCT03166202 - Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator
Completed NCT01397409 - Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD) Phase 2